Expand capacity for demonstration-scale and mid-scale co-manufacturing
Companies entering the alt protein space often struggle to secure line time at demonstration-scale and mid-scale commercial production facilities. Greater availability of mid-scale contract capacity would reduce capital outlays and facilitate scaling, allowing alt protein companies to maintain greater control over their equity and exercise more influence within the supply chain. Contracting production allows for a more modular supply chain, with participants achieving gains from specialization, allowing for better financial and organizational structuring around core competencies.
